Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma

Active:	No
Cancer Type:	Lymphoma Solid Tumor	NCT ID:	NCT01473095
Trial Phases:	Phase I	Protocol IDs:	ARQ 092-101 (primary)
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NCI Full Details:	http://clinicaltrials.gov/show/NCT01473095

Summary

This is an open-label, Phase 1, dose escalation study of oral ARQ 092 administered to
subjects with advanced solid tumors and recurrent malignant lymphoma. The study is
designed to explore the safety, tolerability, pharmacokinetics, and pharmacodynamics of
ARQ 092 and to define a recommended Phase 2 dose of ARQ 092.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.